Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus

Zandbergen, Adrienne A.M.; Baggen, Marinus G.A.; Lamberts, Steven W.J.; Bootsma, Aart H.; de Zeeuw, Dick; Ouwendijk, Rob J.Th.
July 2003
Annals of Internal Medicine;7/15/2003, Vol. 139 Issue 2, p90
Academic Journal
Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotensive and hypertensive diabetic patients. Angiotensin-receptor antagonists reduce urinary albumin excretion and the risk for renal and cardiovascular complications in hypertensive patients with type 2 diabetes mellitus. The effect of angiotensin-receptor antagonists in normotensive diabetic patients with microalbuminuria has not yet been reported. Objective: To assess the antiproteinuric effects of losartan in normotensive patients with type 2 diabetes and microalbuminuria. Design: Multicenter randomized, double-blind, placebo-controlled clinical trial. Setting: 19 outpatient clinics in the Netherlands. Patients: 147 normotensive patients with type 2 diabetes melli-tus and microalbuminuria. Intervention: 74 patients were randomly assigned to receive losartan and 73 patients were assigned to receive placebo for 10 weeks; 71 patients in each group completed the study. The losar-tan dose was 50 mg during the first 5 weeks and 100 mg during the subsequent 5 weeks. Measurements: Change in urinary albumin excretion rate after 5 and 10 weeks, change in creatinine clearance and blood pressure, and safety and tolerability of losartan. Results: A significant 25% relative reduction in the albumin excretion rate occurred after 5 weeks of the 50-mg losartan dose, with further improvement over the subsequent 5 weeks with the 100-mg dose (relative reduction, 34%). In the losartan group, creatinine clearance did not improve and blood pressure decreased slightly. Side effects did not differ between treatment groups. Conclusions: The angiotensin-receptor antagonist losartan reduces urinary albumin excretion in normotensive patients with type 2 diabetes and microalbuminuria. In multivariate analysis, the antiproteinuric effect of losartan was independent of the associated reduction in blood pressure. Losartan was safe and well tolerated in these normotensive patients.


Related Articles

  • Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Ruilope, Luis M.; Alcázar, Jose M.; Hernández, Eduardo; Praga, Manuel; Lahera, Vicente; Rodicio, Jose L. // Kidney International Supplement;Feb1994, Issue 45, pS-171 

    Discusses the importance of the long-term influences of antihypertensive therapy on microalbuminuria in the treatment of hypertension. Comparison of effects between standard therapy and a calcium antagonist on the urinary albumin excretion; Efficacy of standard therapy and converting enzyme...

  • Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study*. Barnett, A. // Acta Diabetologica;Apr2005 Supplement 1, Vol. 42, p42 

    Diabetic nephropathy is characterised by hypertension and persistent proteinuria. If ineffectively controlled, a progressive decline in renal function can result in end-stage renal disease. Patients with diabetic nephropathy are also at greatly increased risk of cardiovascular disease....

  • The Reno-Protective Effect of the Dual Blockade of the Renin Angiotensin System (RAS). Luño, José; Praga, Manuel; de Vinuesa, Soledad García // Current Pharmaceutical Design;Apr2005, Vol. 11 Issue 10, p1291 

    Hypertension and proteinuria are risk factors for renal disease progression. There is clear evidence that pharmacological blockade of the RAS with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) reduces proteinuria and slows down the progression of renal...

  • ACE inhibitors: First-line therapy in diabetes. Glaser, Vicki // Patient Care;4/15/2001, Vol. 35 Issue 7, p103 

    Deals with the treatment for patients with hypertension and type 1 or type 2 diabetes using angiotensin-converting enzyme (ACE) inhibitors. Prevention of the onset of diabetic nephropathy using ACE inhibitors; Role of ACE inhibitors in the reduction of blood pressure; Overview of the side...

  • JournalScan. Lindsay, Alistair // Heart;Feb2010, Vol. 96 Issue 3, p249 

    The article reports on the medical study which explores the clinical effect of novel endothelin antagonist Darusentan on managing patients with hypertension and diabetes. It notes that edema occurred in 27% of research subjects treated with darusentan. Moreover, darusentan is an effective...

  • DIABETES DILEMMA. Krawczyk, Konrad W. // Cortlandt Forum;10/25/2003, Vol. 16 Issue 10, p44 

    Presents a question and answer advisory on the suitability of using lifelong statin and angiotensin converting enzyme inhibitor use by a diabetic. Consideration of the occurrence of hypertension; Reduction of risk of stroke; Citation of studies supporting the therapeutic efficacy of statin.

  • Corticosteroids in treatment of disseminated tuberculosis in patient with HIV infection. Allawi, J.; Rao, P.V.; Gilbert, R.; Scott, G.; Jarrett, R.J.; Keen, H.; Viberti, G.C.; Mather, H.M. // British Medical Journal (Clinical Research Edition);2/13/1988, Vol. 296 Issue 6620, p464 

    Examines the prevalence of non-insulin-dependent diabetes mellitus among British Indians. Comparison between the ratio of albumin to creatinine concentration in Indian and Europid patients; Association between hypertension and raised albumin to creatinine ratio; Concerns on the emergence of...

  • The Adverse Effect Dilemma: Quest for Accessible Information. Roush, Maura K.; McNutt, Robert A.; Gray, T. Flint // Annals of Internal Medicine;2/15/91, Vol. 114 Issue 4, p298 

    Provides information on a study which reported the case of a 23 year old patient who developed pancreatitis while receiving enalapril for hypertension. Overview of cases related to the use of enalapril; Steps taken in an attempt to link enalapril and pancreatitis; Speculation on the influence...

  • Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Tse, K. C.; Li, F. K.; Tang, S.; Tang, C. S.-O.; Lai, K. N.; Chan, T. M. // Lupus;2005, Vol. 14 Issue 12, p947 

    Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) reduces proteinuria and the rate of renal function deterioration in diabetic nephropathy and other glomerular diseases, but its role in quiescent lupus nephritis has not been established. We conducted a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics